Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You are right gregisntnice, I prefer no tweet tomorrow! Just boom...
Lol....
Agreed too early, one more run! Give it a chance!
Nothing wrong with that whale. But this board is not design for that. It should be but it's not!
That's the name of the game whale, you either in it or out! There's pumpers, bashers and flippers sometime could be both pumper and flippers and bashers and flippers!
The company is diluting, they need money! One of the obvious sign you see, is the T trade EOD everyday for the last couple of weeks. Let's just hope they using the money for the development of the company.
Why so bitter whalewatch? I heard you have 20 mill shares that's makes you a bag holder. You lost faith in this stock? Sell it don't become bashers. I've been here long, and you just got in. Everybody who are here long knows that this company making them money.
Get ready for the next run!! It's coming.
T trade again bro!!
I wish I know man!
Yeah man, they been doing that for weeks now.
There you go!
Watch the T trade in a few minute!!
Watch The T trades in a few minute.
What makes you think is investors? Think again!
Yup indeed! Watch the morning break, I think they still gonna try to push it down tomorrow. Till we get a solid PR or news.
Yeah, Thanks to Janice and AXE! They been at it for the longest time. This thing gonna move its just a matter of time not yours not mine! Patience will pay off!
Check out 52 mill t trade after hours.
News is coming!! It's about time..
T trade... here we go again!
There goes the dilution! 28mill T trade
T trade?
They got a lot of products! That's why they are diluting, way too many products as matter a fact. Thinking to to average down my entry but I just gonna wait it out till the dilution stop...
Here comes .0011 power hours let's closed strong people!!
This company diluting this shit out of the PR, obviously they need money. Kickstarter one of the example.. this is not all flippers plays, one ticker play that's ridiculous!
Time to buy, something is coming. The bid .0005 ask at .0007.
Maybe is a leaked, I don't know man. Just doing my DD as share holder.
I sent them an email last night got this first thing in the morning. So I thought they going to release it today. But I guess not.
Company Press Releases:
PROTEXT MOBILITY SIGNS AGREEMENT WITH LEADING RESEARCH CENTER, CIDP, TO CONDUCT DIABETES HUMAN CLINICAL TRIAL
FLORIDA, USA--(Marketwire – May, 2017) – Protext Mobility, Inc. (PINKSHEETS: TXTM) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical applications with highly bioavailable Phytofare® extracts, announced today that it has signed an agreement with the Centre International de Developpment Pharmaceutique (CIDP) to conduct a human clinical trial with its product Phytofare® Catechin Complex, in the country of Mauritius.
The study is titled, Clinical Trial on Humans to determine the efficacy of Phytofare® for lowering HbA1C levels in II Diabetes patients. When glucose builds up in a person’s blood, it binds to the hemoglobin in red blood cells. The HbA1C test measures how much glucose is bound over a 2-3 month period to determine average plasma glucose concentration. The objectives of the study is to determine the efficacy of Phytofare® Catechin Complex for improving the levels of hypoglycemia in people with diabetes as emphasized in the American Diabetes Association's new 2017 Standards of Medical Care in Diabetes. The Company expects to begin phase-one with a bioavailability study this month with CIC Cynologies to confirm the human clinical study dosage of Phytofare® Catechin Complex, with results anticipated for release in June; then followed by the implementation of the Type-II diabetes human clinical trial in the second half of 2017, to be undertaken by CIDP.
Roger Baylis-Duffield, Chief Executive Officer of Protext, commented, “Management recently held extensive meetings with CIDP in Mauritius and were duly impressed with the medical infrastructure and levels of professionalism. Having a qualified team in Mauritius to oversee and manage the human clinical trial is a tremendous asset as the study findings will be subjected to a vigorous peer review, which will subsequently allow the company to apply for an FDA botanical drug status as a dietary supplement. Based on the outcome of the clinical studies, the company will seek to globally license the product to benefit and to improve the lives of people affected by Type II diabetes throughout the world, including to more than 29 million Americans suffering from this disease. The human clinical trial is an important milestone, and next step, for the Company as obtaining a diabetes claim would enable the company to enter into a market where 12% of global health expenditure is spent on diabetes ($673 billion).”
Mrs. Vandana Mungroo, Head of clinical operations CIDP, who will oversee the human clinical trial in Mauritius, added, “We’re excited to work with Protext on a project that is so critical to
the health of Mauritius, where an estimated 25% of the population suffers from Type II Diabetes. Having a complex of active antioxidants available to help regulate glucose levels would be a significant benefit to developing countries where the populations are hardest hit. Multiple third-party studies indicate that green tea catechins show potential for regulating glucose levels however; human clinical research in this field has been hampered due to poor bioavailability and high dosage. We now believe that the higher bioavailability of Phytofare® may overcome these challenges and lead to an all-natural inhibitive and preventative treatment of the disease.”
Phytofare® Catechin Complex is a highly-bioavailable extract produced from live green tea leaves. The unique manufacturing process of Phytofare® yields an end product that contains all eight catechins found in green tea. Human clinical studies have shown that more than ten times Phytofare® catechins are transferred into the blood plasma over generic catechin extracts, where they remain at therapeutic levels for more than 24 hours.
CIDP is a private and independent CRO carrying out high performance research and clinical activities for pharmaceutical, medical device, nutrition and cosmetic industries. With over 12 years of experience in the clinical research, CIDP has now a strong foothold of each continent with centers located in Brazil, India, Mauritius, Romania and Singapore. The services provided are segmented into five main areas of expertise:
Research & Innovation, Preclinical (Invitro) Clinical, Biostatistics and Data and Regulatory Affairs. CIDP has also developed an independent Global Quality Assurance department which monitors their studies worldwide. All subsidiaries are ISO 9001 certified. For additional information visit www.cidp-cro.com.
I hope this help!!
Protext.Press Releases.1.1.pdf
Not gonna happen!! PR coming soon..
Elvis, time to buy my man!! Come on don't be shy..
I guess you gonna be here next week too, right!!!!
T trade? why is my e-trade showing at .0025?